SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:56S1 • FR0013154002
191.6 EUR
-6.05 (-3.06%)
Last: Jan 29, 2026, 07:00 PM
56S1 gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 22 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of 56S1 get a neutral evaluation. Nothing too spectacular is happening here. 56S1 is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- 56S1 had positive earnings in the past year.
- 56S1 had a positive operating cash flow in the past year.
- Each year in the past 5 years 56S1 has been profitable.
- Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 3.36%, 56S1 is doing worse than 63.64% of the companies in the same industry.
- 56S1's Return On Equity of 6.55% is in line compared to the rest of the industry. 56S1 outperforms 40.91% of its industry peers.
- 56S1 has a Return On Invested Capital (5.94%) which is in line with its industry peers.
- 56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is in line with the industry average of 9.34%.
- The last Return On Invested Capital (5.94%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.36% | ||
| ROE | 6.55% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
- 56S1 has a Profit Margin (8.98%) which is in line with its industry peers.
- In the last couple of years the Profit Margin of 56S1 has declined.
- 56S1 has a Operating Margin of 16.63%. This is in the better half of the industry: 56S1 outperforms 63.64% of its industry peers.
- 56S1's Operating Margin has declined in the last couple of years.
- 56S1 has a Gross Margin (45.64%) which is in line with its industry peers.
- 56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.98% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
- The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
- 56S1 has more shares outstanding than it did 5 years ago.
- 56S1 has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 4.21 indicates that 56S1 is not in any danger for bankruptcy at the moment.
- 56S1's Altman-Z score of 4.21 is fine compared to the rest of the industry. 56S1 outperforms 77.27% of its industry peers.
- 56S1 has a debt to FCF ratio of 6.84. This is a slightly negative value and a sign of low solvency as 56S1 would need 6.84 years to pay back of all of its debts.
- 56S1 has a Debt to FCF ratio (6.84) which is comparable to the rest of the industry.
- 56S1 has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
- The Debt to Equity ratio of 56S1 (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.21 |
ROIC/WACC0.61
WACC9.69%
2.3 Liquidity
- A Current Ratio of 1.05 indicates that 56S1 should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.05, 56S1 is doing worse than 72.73% of the companies in the same industry.
- 56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.50, 56S1 is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 35.11% over the past year.
- The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
- The Revenue has been growing slightly by 7.72% in the past year.
- The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
- The Earnings Per Share is expected to grow by 21.17% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 9.86% on average over the next years. This is quite good.
EPS Next Y29.12%
EPS Next 2Y23.48%
EPS Next 3Y22.85%
EPS Next 5Y21.17%
Revenue Next Year7.45%
Revenue Next 2Y8.04%
Revenue Next 3Y9.07%
Revenue Next 5Y9.86%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 44.45 indicates a quite expensive valuation of 56S1.
- Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 77.27% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 28.30, 56S1 is valued quite expensively.
- A Price/Forward Earnings ratio of 35.90 indicates a quite expensive valuation of 56S1.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 72.73% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of 56S1 to the average of the S&P500 Index (25.57), we can say 56S1 is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.45 | ||
| Fwd PE | 35.9 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 77.27% of the companies listed in the same industry.
- The rest of the industry has a similar Price/Free Cash Flow ratio as 56S1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 49.78 | ||
| EV/EBITDA | 25.87 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as 56S1's earnings are expected to grow with 22.85% in the coming years.
PEG (NY)1.53
PEG (5Y)10.6
EPS Next 2Y23.48%
EPS Next 3Y22.85%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.36%, 56S1 is not a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 0.51, 56S1 has a dividend in line with its industry peers.
- With a Dividend Yield of 0.36, 56S1 pays less dividend than the S&P500 average, which is at 1.83.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.36% |
5.2 History
- The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
- 25.37% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
- The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.37%
EPS Next 2Y23.48%
EPS Next 3Y22.85%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.
Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for 56S1 stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 44.45 and the Price/Book (PB) ratio is 4.62.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 29.12% in the next year.